Probiotec Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
903.70
24,742.30
4,013.50
3,304.30
4,976.90
Depreciation, Depletion & Amortization
4,473.60
4,350.80
2,858.90
2,788.00
3,008.50
Other Funds
1,818.70
24,430.20
1,861.60
930.50
999.50
Funds from Operations
3,460.40
3,080.50
5,843.70
6,197.90
9,298.20
Changes in Working Capital
1,845.50
756.20
801.50
2,109.90
3,075.30
Net Operating Cash Flow
5,305.90
2,324.20
5,042.20
4,088.00
6,222.90
Capital Expenditures
4,287.40
2,732.50
3,574.70
3,247.10
5,512.80
Sale of Fixed Assets & Businesses
45.40
1,923.30
6,523.60
39.60
-
Net Investing Cash Flow
5,758.00
809.20
2,948.90
3,207.50
9,715.20
Cash Dividends Paid - Total
-
-
-
1,058.60
1,250.20
Issuance/Reduction of Debt, Net
8,565.90
2,511.30
7,605.80
-
-
Net Financing Cash Flow
8,565.90
2,511.30
7,605.80
1,064.50
4,986.80
Net Change in Cash
2,498.10
996.30
385.30
184.00
1,494.50
Free Cash Flow
2,701.50
520.80
2,447.70
1,576.00
1,624.30
Deferred Taxes & Investment Tax Credit
98.20
958.20
832.90
1,036.10
2,312.30
Net Assets from Acquisitions
-
-
-
-
4,202.40
Other Sources
10,000.00
-
-
-
-
Change in Capital Stock
-
-
-
-
850.00

About Probiotec

View Profile
Address
83 Cherry Lane
Melbourne Victoria (VIC) 3026
Australia
Employees -
Website http://www.probiotec.com.au
Updated 07/08/2019
Probiotec Ltd. engages in manufacture, market and distribution of over-the-counter pharmaceuticals, complementary medicines and specialty ingredients. It operates through the following segments: Branded Pharmaceuticals, Contract Manufacturing, Obesity and Weight Management, Europe, and Specialty Products. The Branded Pharmaceuticals segment involves the sale of branded pharmaceutical products.